Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

Area of Science:

• Biochemistry
• Structural Biology
• Oncology

Background:

• Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase implicated in various human cancers.
• ALK is a validated therapeutic target for ALK-positive malignancies, driving the development of small-molecule inhibitors.

Purpose of the Study:

• To elucidate the structural basis of ALK inhibition by ATP-competitive ligands.
• To identify key features of the ALK active site for selective inhibitor design.
• To explore potential regulatory mechanisms and the impact of activating mutations.

Main Methods:

• X-ray crystallography was employed to determine the structures of the human ALK kinase domain.
• Complex structures were solved for ALK in conjunction with the ligands PHA-E429 and NVP-TAE684.
• Structural analysis included mapping of known ALK-activating mutations.

Main Results:

• Crystal structures of the unphosphorylated human ALK kinase domain complexed with PHA-E429 and NVP-TAE684 were determined.
• The structures reveal specific characteristics of the ALK active site, guiding the design of selective inhibitors.
• A potential regulatory mechanism involving a helical segment and a beta-sheet was identified.
• Mapping of neuroblastoma-associated mutations provided insights into ALK activation.

Conclusions:

• The determined ALK structures offer a foundation for rational drug design of targeted cancer therapies.
• Understanding the ALK active site and regulatory elements can lead to more effective and selective ALK inhibitors.
• Structural analysis of mutations clarifies their role in ALK-driven oncogenesis.